Uranium ETF Gains 4.9% on August 4 as Centrus Energy Backlog and DOE Contract Draw Buyers Back
A $3.9 billion order book and $900 million DOE contract are pulling investors back to Centrus Energy, though a Q1 earnings miss complicates the case.
The URA uranium ETF gained 4.91% to $40.81 on August 4 (2026-08-04), lifting scrutiny onto domestic U.S. nuclear fuel suppliers and, in particular, onto Centrus Energy — the company central to Washington's push to rebuild American enrichment capacity.4
Centrus shares had already jumped 10.68% on July 30 (2026-07-30), per Motley Fool data at the time of publication, after analysis pointed to the scale of the company's contracted revenue. At the end of Q1 2026, Centrus held a $3.9 billion order backlog, a record, stretching to 2040. Roughly $3.1 billion of that comes from the low-enriched uranium segment, the standard fuel for the existing U.S. reactor fleet.5
The backlog is long-dated and largely fixed. Centrus ended Q1 2026 with approximately $1.8 billion in cash, cash equivalents, and restricted cash. Quarterly revenue came in at $76.7 million, with GAAP net income of $10 million. That liquidity position means the company can absorb uranium spot price weakness without accessing capital markets, a material advantage in a sector where prices were still retreating from January 2026 highs by the May 20 (2026-05-20) session.4,1
The spring was difficult. Centrus shares dropped 8.8% around May 9 (2026-05-09), roughly 11 days before a StockStory note dated May 20 (2026-05-20), when Q1 2026 results missed analyst expectations and analysts subsequently trimmed forward earnings projections. The stock then fell a further 5.4% on May 20 (2026-05-20) as spot uranium slipped to $85.95 per pound, extending a multi-month retreat from the year's highs. Two back-to-back sell-offs in three weeks showed how quickly sentiment can reverse when operational results disappoint in a commodity-linked equity.1
Yet the structural case has not changed. The Department of Energy awarded Centrus a contract worth up to $900 million to establish a domestic supply chain for high-assay low-enriched uranium, known as HALEU, the fuel required by advanced reactor designs currently under development across the country. Washington has designated domestic nuclear fuel supply an urgent national security priority.3,4
A hard deadline underpins that designation. A U.S. ban on Russian uranium imports takes effect in 2028, removing a supply source that has historically filled gaps in domestic enrichment capacity. The ban arrives as demand-side forces strengthen from multiple directions: utilities are extending the operating lives of existing reactors, and technology companies are exploring nuclear power contracts to supply electricity for AI data centers. Both pull in the same direction for enrichment demand.5,3
Institutional positioning has tracked the policy momentum. An SEC filing dated May 14 (2026-05-14) showed RPG Investment Advisory initiating a new Centrus position, purchasing 50,460 shares. The stake was valued at $8.76 million at the March 31, 2026 quarter-end.2
The debate is essentially a sequencing argument. The backlog, the DOE contract, and the 2028 import ban all point to a demand environment that should, over time, absorb domestic enrichment capacity and justify higher pricing power for Centrus. But Q1 results missed the bar, analysts cut estimates rather than raised them, and spot uranium prices had not, as of the May 20 (2026-05-20) session, recovered from their January retreat. August 4's URA gain is an equity market signal, not a fuel contract; the gap between enrichment company fundamentals and uranium ETF flows can stay wide for extended periods.1,4
Second-quarter results and DOE milestone updates on HALEU production are the next concrete test. A Q2 earnings beat would give the backlog thesis the operational backing it currently lacks. Another miss would raise questions about execution capacity at the moment the government is counting on Centrus to deliver.1,4,3